Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Down 27.1% in April

Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 14,360,000 shares, a decrease of 27.1% from the March 31st total of 19,710,000 shares. Based on an average daily volume of 59,870,000 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Jaguar Health in a research note on Monday, April 22nd. They set a “sell” rating for the company.

Jaguar Health Stock Up 5.9 %

JAGX stock traded up $0.01 during trading on Friday, reaching $0.18. 43,999,118 shares of the company’s stock were exchanged, compared to its average volume of 84,090,512. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. Jaguar Health has a 1-year low of $0.05 and a 1-year high of $1.22. The company’s fifty day moving average price is $0.10 and its 200-day moving average price is $0.18.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.